ProPharma’s team of dedicated experts is at the forefront of both existing and emerging industry trends. ProPharma’s team inspires tomorrow by leveraging rich data insights across our service lines and functional areas to develop innovative solutions that answer the most complex needs of both existing and prospective clients.
Digital Transformation in Life Sciences: The Importance of Data Strategy
What is Digital Transformation?
While there are many different definitions of digital transformation in life sciences, the core concepts they all have in common are digital technology and creating new, or modifying existing, ways of working. The underlying business driver is that digital...
Direct-to-Consumer (DTC) Drug Advertisements, Part Two
FDA to Study How Superimposed Text in Direct-to-Consumer Drug Ads Impacts Consumer Comprehension Over the past few weeks, the FDA announced plans to launch public surveys and conduct studies relating...
Direct-to-Consumer (DTC) Drug Advertisements, Part One
FDA is planning to do some major housekeeping when it comes to direct-to-consumer (DTC) drug advertisements. Based on a number of recent announcements, the Agency is planning to study various aspects...
ISO 13485 – Requirements for Medical Device Quality Management Systems
On February 25, 2016, the International Organization for Standardization (ISO) published its updated ISO 13485 guidance. The guidance, which was originally published in 2003, is the global standard...
As we’ve now moved on from another cold winter month, I was captivated recently thinking about Quality Assurance and our collective responsibilities. All kinds of things come to mind; Deviations,...
FDA to Review PhUSE Nonclinical Study Data Reviewer’s Guide Template
As a part of its ongoing collaboration with the Pharmaceutical Users Software Exchange (PhUSE), the FDA has announced its plans to review the proposed Nonclinical Study Data Reviewer’s Guide (SDRG)...
Opioid Epidemic: Everything You Need to Know About FDA’s Action Plan to Reduce Opioid Abuse
Additional details on the opioid epidemic are available in our FDA News article, entitled "Califf Pledges to Review FDA’s Opioid Policies to Address US Opioid Epidemic" In early February, Dr. Robert...
FDA Takes Steps to Ensure Patients are Informed of Safety Risks Associated with Essure
Additional information on FDA's review of Essure is available in our previous FDA News article entitled "Coming Soon: FDA Safety Review of Essure" On Monday, February 29th, FDA announced that it will...
Effectiveness of DTC Drug Advertisements – FDA to Survey Patients About Impact of Ads
Late last month, FDA announced plans to launch a public survey to ask patients about their experiences with direct-to-consumer (DTC) drug advertisements. Background In 2002, the FDA surveyed patients...
Data integrity is a current hot topic, but not a new one, within the life sciences industries and associated product supply chains. This article will not delve into why there have been so many recent...
Understanding Statistical Intervals: Part 2 - Prediction Intervals
Part 1 of this series discussed confidence intervals. Confidence intervals are the best known of the statistical intervals but they only bound regions associated with population parameters; i.e., the...
In order to incentivize the development of therapies (drugs biologics) to fill unmet medical needs for treatment of serious conditions, the FDA has developed various programs to expedite drug...
What is a Clinical Study Report? A Clinical Study Report (CSR) is a document that describes the methods and results of a clinical study or trial, along with a short discussion of key findings related...
Patient Support Programs (PSPs) in the pharmaceutical sector represent an array of aimed at supporting patients in initiating therapy and maintaining adherence. PSPs, also known as Patient Assistance...
The link between statistical methods and healthcare is not a new one, but the volume of available data to inform healthcare decisions and the use of data science in the medical industry has exploded...
Formal FDA Meetings for Sponsors or Applications of PDUFA Products
This article has been updated since its original February 28, 2017 publication. Since the introduction of the Prescription Drug User Fee Act (PDUFA) VII for fiscal years 2023 - 2027, the FDA...